Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Ohta

Showing results (201-210 of 243) with videos related to

Pageof 25
Sort By:
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|December 15, 2020
IL-1RA in the supernatant of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus is useful for discriminating active tuberculosis from latent infectionShunsuke Akashi, Maho Suzukawa, Keita Takeda, et al.
Tuberculosis (Edinburgh, Scotland)|August 9, 2022
Evaluation of tuberculosis diagnostic biomarkers in immunocompromised hosts based on cytokine levels in QuantiFERON-TB Gold PlusSahoko Imoto, Maho Suzukawa, Keita Takeda, et al.
The Journal of Infection|February 25, 2020
Evaluation of cytokine levels using QuantiFERON-TB Gold Plus in patients with active tuberculosisMaho Suzukawa, Keita Takeda, Shunsuke Akashi, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 3, 2020
Clinical risk factors related to treatment failure in Mycobacterium abscessus lung diseaseKeiji Fujiwara, Koji Furuuchi, Akio Aono, et al.
ERJ Open Research|August 12, 2025
Risk factors, molecular analysis and treatment outcomes of amikacin-resistant <i>Mycobacterium avium</i> complex pulmonary diseaseTatsuya Kodama, Akio Aono, Keiji Fujiwara, et al.
Molecular Genetics & Genomic Medicine|July 5, 2019
Recurring large deletion in DRC1 (CCDC164) identified as causing primary ciliary dyskinesia in two Asian patientsKozo Morimoto, Minako Hijikata, Maimoona A Zariwala, et al.
Lancet (London, England)|September 10, 2016
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialJ Mark FitzGerald, Eugene R Bleecker, Parameswaran Nair, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|October 16, 2020
Analysis of risk factors for the development of a post-bronchoscopy respiratory infection in lung cancer patientsMasafumi Shimoda, Kazunari Yamana, Ryozo Yano, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|November 26, 2015
Thoracoscopic examination of empyema in a patient with sparganosis mansoniKeita Takeda, Junko Suzuki, Hideaki Nagai, et al.
ERJ Open Research|February 23, 2023
Epidemiological characteristics of nontuberculous mycobacteriosis and bronchiectasis: comparative study using national mortality statistics from 1970 to 2015 in JapanKozo Morimoto, Kazuro Iwai, Takashi Yoshiyama, et al.
Pageof 25

Showing results (201-210 of 243) with videos related to

Sort By:
Pageof 25
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|December 15, 2020
IL-1RA in the supernatant of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus is useful for discriminating active tuberculosis from latent infectionShunsuke Akashi, Maho Suzukawa, Keita Takeda, et al.
Tuberculosis (Edinburgh, Scotland)|August 9, 2022
Evaluation of tuberculosis diagnostic biomarkers in immunocompromised hosts based on cytokine levels in QuantiFERON-TB Gold PlusSahoko Imoto, Maho Suzukawa, Keita Takeda, et al.
The Journal of Infection|February 25, 2020
Evaluation of cytokine levels using QuantiFERON-TB Gold Plus in patients with active tuberculosisMaho Suzukawa, Keita Takeda, Shunsuke Akashi, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 3, 2020
Clinical risk factors related to treatment failure in Mycobacterium abscessus lung diseaseKeiji Fujiwara, Koji Furuuchi, Akio Aono, et al.
ERJ Open Research|August 12, 2025
Risk factors, molecular analysis and treatment outcomes of amikacin-resistant <i>Mycobacterium avium</i> complex pulmonary diseaseTatsuya Kodama, Akio Aono, Keiji Fujiwara, et al.
Molecular Genetics & Genomic Medicine|July 5, 2019
Recurring large deletion in DRC1 (CCDC164) identified as causing primary ciliary dyskinesia in two Asian patientsKozo Morimoto, Minako Hijikata, Maimoona A Zariwala, et al.
Lancet (London, England)|September 10, 2016
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialJ Mark FitzGerald, Eugene R Bleecker, Parameswaran Nair, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|October 16, 2020
Analysis of risk factors for the development of a post-bronchoscopy respiratory infection in lung cancer patientsMasafumi Shimoda, Kazunari Yamana, Ryozo Yano, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|November 26, 2015
Thoracoscopic examination of empyema in a patient with sparganosis mansoniKeita Takeda, Junko Suzuki, Hideaki Nagai, et al.
ERJ Open Research|February 23, 2023
Epidemiological characteristics of nontuberculous mycobacteriosis and bronchiectasis: comparative study using national mortality statistics from 1970 to 2015 in JapanKozo Morimoto, Kazuro Iwai, Takashi Yoshiyama, et al.
Pageof 25